On the afternoon of November 26, accompanied by the leaders of Shenzhen Nanshan District Science and Technology Bureau, CPPCC Vice Chairman Lu Yuping led a delegation of Nanshan CPPCC committee members to visit ISKCON's headquarters to inspect and investigate the company.

The 21-member delegation consisted of many experts including medical treatment. Shi Pengyan, the company's project manager, gave a work report to the delegation and introduced in detail the research and development results and application of ISKCON's ACTL targeted anti-tumor cell immune technology.

Afterwards, the delegation visited the company's 1100 square meter laboratory to learn more about the cell preparation process and watched the cell preparation operation.

Vice Chairman Lu Yuping and his party fully affirmed the work of ISKCON and encouraged the team of ISKCON to continue to use its technological advantages, innovate continuously, and make great contributions to the anti-tumor cause.

Shenzhen Yishi Kangning Biotechnology Co., Ltd. was established in 2012 and has been focusing on the research and development of ACTL targeted anti-tumor cellular immunity technology. The safety and effectiveness of this technology are in an international leading position. At present, more than 30 tertiary and first-class hospitals have launched scientific research cooperation with ISKCON. Through the participation of multidisciplinary experts in the hospital, ACTL technology will be continuously upgraded to provide better services to patients.